METHOD FOR PREVENTING AND TREATING LIPID METABOLISM DISORDERS AND RELATED DISEASES THEREOF

• US 20190328850A1
• Filed: 06/19/2017
• Published: 10/31/2019
• Est. Priority Date: 12/15/2016
• Status: Abandoned Application

• Current Assignee: Talengen International Limited
• Original Assignee: Talengen International Limited
• Inventors: LI, Jinan
• Application Number:
  US16/470,174
• Publication Number:
  US 20190328850A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 38/484 Plasmin (3.4.21.7)
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12Y 304/21007 Plasmin (3.4.21.7), i.e. fibrinolysin
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a method for preventing and/or treating a fat metabolism disorder and its related conditions, comprising administering an effective amount of plasminogen to a subject susceptible to or suffering from a fat metabolism disorder and its related conditions, to reduce an abnormal fat deposition at various sites of the body, thereby achieving the purpose of preventing and/or treating a fat metabolism disorder and its related conditions or complications.

Claims

1. :

A method for preventing and/or treating a fat metabolism disorder and its related conditions in a subject, comprising administering a prophylactically and/or therapeutically effective amount of plasminogen to the subject, wherein the subject is susceptible to a fat metabolism disorder, suffers from a fat metabolism disorder or other diseases accompanied by a fat metabolism disorder.

2. :

The method of claim 1, wherein the fat metabolism disorder is a fat metabolism disorder elicited or accompanied by an endocrine disorder disease, a glucose metabolism disease, a liver disease, a kidney disease, a cardiovascular disease, an intestinal disease, a thyroid disease, a gallbladder or a biliary tract disease, obesity, drinking, and a drug therapy.

3. :

The method of claim 2, wherein the fat metabolism disorder is a fat metabolism disorder elicited or accompanied by hypertension, diabetes mellitus, chronic hepatitis, hepatic cirrhosis, renal injury, chronic glomerulonephritis, chronic pyelonephritis, nephrotic syndrome, renal insufficiency, kidney transplantation, uremia, hypothyroidism, obstructive cholecystitis, obstructive cholangitis, and a drug or hormone therapy.

4. :

The method of claim 1, wherein the fat metabolism disorder is hyperlipemia, hyperlipoproteinemia, fatty liver, atherosclerosis, obesity, and a visceral fat deposition.

5. :

The method of claim 4, wherein the atherosclerosis comprises aortic atherosclerosis, coronary atherosclerosis, cerebral atherosclerosis, renal atherosclerosis, hepatic atherosclerosis, mesenteric atherosclerosis, and lower limb atherosclerosis.

24. :

The method of claim 1, wherein the plasminogen is administered in combination with one or more other drugs or therapies.

25. :

The method of claim 24, wherein the one or more other drugs comprises a hypolipidemic drug, an anti-platelet drug, an antihypertensive drug, a vasodilator, a hypoglycemic drug, an anticoagulant drug, a thrombolytic drug, a hepatoprotective drug, an anti-arrhythmia drug, a cardiotonic drug, a diuretic drug, an anti-infective drug, an antiviral drug, an immunomodulatory drug, an inflammatory regulatory drug, an anti-tumor drug, a hormone drug, and thyroxine.

27. :

The method of claim 25, wherein the drugs comprise hypolipidemic drugs;

statins;

fibrates;

niacin;

cholestyramine;

clofibrate;

unsaturated fatty acids such as Yishouning, Xuezhiping, and Xinmaile; and

alginic sodium diester;

anti-platelet drugs;

aspirin;

dipyridamole;

clopidogrel; and

cilostazol;

vasodilators;

hydralazine;

nitroglycerin, and isosorbide dinitrate;

sodium nitroprusside;

α

1-receptor blockers such as prazosin;

α

-receptor blockers such as phentolamine;

β

2-receptor stimulants such as salbutamol;

captopril, enalapril;

nifedipine, diltiazem; and

salbutamol, loniten, prostaglandin, and atrial natriuretic peptide;

thrombolytic drugs;

urokinase, and streptokinase;

tissue-type plasminogen activators;

single chain urokinase-type plasminogen activators; and

a TNK tissue-type plasminogen activator; and

anticoagulant drugs;

heparin;

enoxaparin;

nadroparin; and

bivalirudin.

28. :

The method of claim 1, wherein the plasminogen has at least 75% sequence identity with SEQ ID No. 2, and still has the plasminogen activity.

30. :

The method of claim 1, wherein the plasminogen is a protein that comprises a plasminogen active fragment and still has the plasminogen activity.

31. :

The method of claim 1, wherein the plasminogen is selected from Glu-plasminogen, Lys-plasminogen, mini-plasminogen, micro-plasminogen, delta-plasminogen or their variants that retain the plasminogen activity.

32. :

The method of claim 1, wherein the plasminogen is a natural or synthetic human plasminogen, or a variant or fragment thereof that still retains the plasminogen activity.

47. :

The method of claim 1, wherein the plasminogen is administered to the subject at a dosage of 1-100 mg/kg at a frequency of weekly to daily.

48. :

The method of claim 47, wherein the dosage of the plasminogen is repeated at least once.

49. :

The method of claim 47, wherein the plasminogen is administered at least daily.

6. :

A method for preventing and/or reducing an abnormal fat deposition in a body tissue and an organ of a subject, comprising administering an effective amount of plasminogen to the subject.

8. :

The method of claim 6, wherein the abnormal fat deposition in a body tissue and an organ refers to an abnormal fat deposition in blood, a subcutaneous tissue, a vascular wall, and an internal organ.

9. :

The method of claim 8, wherein the condition resulting from the abnormal fat deposition in a body tissue and an organ comprises obesity, hyperlipemia, hyperlipoproteinemia, fatty liver, atherosclerosis, a lipid-induced cardiac damage, a lipid-induced renal damage, and a lipid-induced islet damage.

7. (canceled)

10-15. -15. (canceled)

16. :

A method for ameliorating hyperlipemia, preventing and/or treating a hyperlipemia-related condition in a subject, comprising administering an effective amount of plasminogen to the subject.

17. :

The method of claim 16, wherein the hyperlipemia is selected from one or more of;

hypercholesterolemia, hypertriglyceridemia, combined hyperlipemia, and hypo-high-density lipoproteinemia.

23. :

The method of claim 16, wherein the hyperlipemia-related condition comprises diabetes mellitus, hypertension, atherosclerosis, coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, chronic hepatitis, fatty liver, hepatic cirrhosis, cerebral circulation insufficiency, cerebral ischemia, cerebral infarction, chronic nephritis, chronic pyelonephritis, renal insufficiency, nephrotic syndrome, uremia, and obesity.

18-22. -22. (canceled)

26. (canceled)

29. (canceled)

33-46. -46. (canceled)